Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, Tonizzo A, Fava M, Valzano AG, Morlacchi LC, Donato MF, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A.
Lombardi A, et al. Among authors: castellano g.
Biomedicines. 2023 May 26;11(6):1540. doi: 10.3390/biomedicines11061540.
Biomedicines. 2023.
PMID: 37371635
Free PMC article.